EBE – the European Trade Association representing biopharmaceutical companies of all sizes.
About EBE
26 Nov 2018

Health industries call for a rapid adoption of Horizon Europe, its missions and partnerships

Brussels, 26 November 2018 - Health industries call for a rapid adoption of Horizon Europe, its missions and partnerships  The six undersigned European health industry associations are ambitious...

Read more
10 Jul 2018

New EBE-EFPIA study demonstrates benefits of personalised medicine for patients, society and healthcare systems and makes recommendations for equitable access for patients in Europe

The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) released today the outcome of the evidence-based analysis on personal...

Read more
02 Jul 2018

EBE announces its 2018-2020 Board of Directors

Brussels, 2 July 2018 – The European Biopharmaceutical Enterprises (EBE), is pleased to announce its Board of Directors for 2018-2020, following the decisions taken at the EBE Annual Meeting on 26 J...

Read more
19 Oct 2018

EBE-EFPIA Position Paper on Next Generation Sequencing (NGS)

Next generation sequencing (NGS), also known as high-throughput sequencing, is a DNA and RNA sequencing technology which has revolutionized genomic research. Today, an entire human genome can b...

Read more
06 Sep 2018

Joint EBE-EFPIA Position on CE Marking

A Topic Group of the joint Personalised Medicine Working Group has been developing a slide deck highlighting the position of the pharmaceutical industry on the need to consider a risk-based a...

Read more
02 Aug 2018

EBE View on the SPC Manufacturing Waiver

The European Biopharmaceutical Enterprises (EBE) has just released its latest position paper, raising concerns on how the SPC manufacturing waiver will affect innovative biopharmaceutical companies,...

Read more
20 Jun 2018

Incentives, IP and Smaller Companies: The Story of uniQure

Download the Case Story in PDF format here uniQure, based in Amsterdam in the Netherlands  and Lexington, Massachusetts, USA, is developing curative gene therapies for patients with severe geneti...

Read more
07 Jun 2018

KPMG Report: Site Selection for Life Sciences Companies in Europe 2018

EBE supports the 2018 version of the KPMG report on site selection for life science companies in Europe, developed in collaboration with Venture Valuation. Each company seeking to establish European...

Read more
14 Mar 2018

European Investment Bank Report: “Financing the next wave of medical breakthroughs – What works and what needs fixing?”

EBE was proud to support the launch of the European Investment Bank's report "Access-to-finance conditions for Life Sciences R&D" at BioEurope Spring. This reports identifies a number of necessary...

Read more

From Twitter

MIMESIS NEWSLETTER #4, December 2018

After two years, ENYO Pharma’s #EU funded #MIMESIS project was a real success and has delivered several promising new #drug development starting points most significantly for #RSV and #ICD. To learn more: https://t.co/0jFqQ0TBYZ

Fantastic news and work 👏🏻👏🏻👏🏻👏🏻👏🏻👌🏻 https://t.co/lN4hn0ICmN

So important to note. On the other hand, #IntellectualProperty, #IP fuels innovation, especially by small players like #SME who need a reliable #IP environment to secure funding for their work.

Follow us